Diagnostic tests and treatment options in glomerular disease: 2014 update

American Journal of Kidney Diseases

Volumn 63, Issue 4, 2014, Pages 656-666

  Hogan, Jonathan ^a   Mohan, Prince ^a   Appel, Gerald B ^a,b  

^a Department of Medicine   (United States)

^b NONE   (United States)

Author keywords

C3 glomerulopathies; focal segmental glomerulosclerosis; glomerular disease; Immunoglobulin A (IgA) nephropathy; membranous nephropathy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; GOLD STANDARD; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY INJURY; MEMBRANOUS GLOMERULONEPHRITIS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

C3 GLOMERULOPATHIES; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; GLOMERULAR DISEASE; IMMUNOGLOBULIN A (IGA) NEPHROPATHY; MEMBRANOUS NEPHROPATHY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; COMPLEMENT C3; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, IGA; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84897109632     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.09.019     Document Type: Review

References (120)

1. G. D'Amico The commonest glomerulonephritis in the world: IgA nephropathy Q J Med 64 245 1987 709 727
2. Y. Nishitani, M. Iwano, and Y. Yamaguchi et al. Fibroblast-specific protein 1 is a specific prognostic marker for renal survival in patients with IgAN Kidney Int 68 3 2005 1078 1085
3. J. Xie, K. Kiryluk, and W. Wang et al. Predicting progression of IgA nephropathy: new clinical progression risk score PloS One 7 6 2012 e38904
4. Working Group of the International IgA Nephropathy Network, the Renal Pathology Society D.C. Cattran et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification Kidney Int 76 5 2009 534 545
5. Working Group of the International Ig ANN, the Renal Pathology Society I.S. Roberts et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility Kidney Int 76 5 2009 546 556
6. Z. Moldoveanu, R.J. Wyatt, and J.Y. Lee et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels Kidney Int 71 11 2007 1148 1154
7. F. Berthoux, H. Suzuki, and L. Thibaudin et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy J Am Soc Nephrol 23 9 2012 1579 1587
8. K. Kiryluk, Z. Moldoveanu, and J.T. Sanders et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch- Schönlein purpura nephritis Kidney Int 80 1 2011 79 87
9. A.G. Gharavi, K. Kiryluk, and M. Choi et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy Nat Genet 43 4 2011 321 327
10. X.Q. Yu, M. Li, and H. Zhang et al. A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy Nat Genet 44 2 2012 178 182
11. R. Sinniah Occurrence of mesangial IgA and IgM deposits in a control necropsy population J Clin Pathol 36 3 1983 276 279
12. J. Varis, I. Rantala, and A. Pasternack Immunofluorescence of immunoglobulins and complement in kidneys taken at necropsy J Clin Pathol 42 11 1989 1211 1214
13. R. Waldherr, M. Rambausek, W.D. Duncker, and E. Ritz Frequency of mesangial IgA deposits in a non-selected autopsy series Nephrol Dial Transplant 4 11 1989 943 946
14. K. Suzuki, K. Honda, K. Tanabe, H. Toma, H. Nihei, and Y. Yamaguchi Incidence of latent mesangial IgA deposition in renal allograft donors in Japan Kidney Int 63 6 2003 2286 2294
15. R. Camilla, H. Suzuki, and V. Dapra et al. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy Clin J Am Soc Nephrol 6 8 2011 1903 1911
16. N. Zhao, P. Hou, and J. Lv et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression Kidney Int 82 7 2012 790 796
17. R. Coppo, L. Peruzzi, and A. Amore et al. IgACE: A placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria J Am Soc Nephrol 18 6 2007 1880 1888
18. P.K. Li, C.B. Leung, and K.M. Chow et al. Hong Kong Study Using Valsartan in IgA Nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study Am J Kidney Dis 47 5 2006 751 760
19. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guidelines for Glomerulonephritis Kidney Int Suppl 2 2012 139 274
20. I. Maeda, T. Hayashi, and K.K. Sato et al. Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy Nephrol Dial Transplant 27 7 2012 2806 2813
21. J.V. Donadio Jr., J.P. Grande, E.J. Bergstralh, R.A. Dart, T.S. Larson, and D.C. Spencer The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group J Am Soc Nephrol 10 8 1999 1772 1777
22. R.J. Hogg, L. Fitzgibbons, C. Atkins, N. Nardelli, and R.C. Bay North American IgA Nephropathy Study Group. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent Clin J Am Soc Nephrol 1 6 2006 1167 1172
23. J. Radhakrishnan, and D.C. Cattran The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines - application to the individual patient Kidney Int 82 8 2012 840 856
24. C. Pozzi, P.G. Bolasco, and G.B. Fogazzi et al. Corticosteroids in IgA nephropathy: A randomised controlled trial Lancet 353 9156 1999 883 887
25. C. Pozzi, S. Andrulli, and L. Del Vecchio et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial J Am Soc Nephrol 15 1 2004 157 163
26. C. Manno, D.D. Torres, M. Rossini, F. Pesce, and F.P. Schena Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy Nephrol Dial Transplant 24 12 2009 3694 3701
27. J. Lv, H. Zhang, and Y. Chen et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial Am J Kidney Dis 53 1 2009 26 32
28. J. Lv, D. Xu, and V. Perkovic et al. Corticosteroid therapy in IgA nephropathy J Am Soc Nephrol 23 6 2012 1108 1116
29. H.K. Smerud, P. Barany, and K. Lindstrom et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria Nephrol Dial Transplant 26 10 2011 3237 3242
30. F.W. Ballardie, and I.S. Roberts Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy J Am Soc Nephrol 13 1 2002 142 148
31. C. Pozzi, S. Andrulli, and A. Pani et al. IgA nephropathy with severe chronic renal failure: A randomized controlled trial of corticosteroids and azathioprine J Nephrol 26 1 2013 86 93
32. X. Chen, P. Chen, and G. Cai et al. [A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy] Zhonghua Yi Xue Za Zhi 82 12 2002 796 801
33. B.D. Maes, R. Oyen, and K. Claes et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study Kidney Int 65 5 2004 1842 1849
34. G. Frisch, J. Lin, and J. Rosenstock et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: A double-blind randomized controlled trial Nephrol Dial Transplant 20 10 2005 2139 2145
35. S. Tang, J.C. Leung, and L.Y. Chan et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy Kidney Int 68 2 2005 802 812
36. S.C. Tang, A.W. Tang, S.S. Wong, J.C. Leung, Y.W. Ho, and K.N. Lai Long-term study of mycophenolate mofetil treatment in IgA nephropathy Kidney Int 77 6 2010 543 549
37. A.S. Bomback, J.A. Tumlin, and J. Baranski et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel Drug Des Devel Ther 5 2011 147 153
38. A.S. Bomback, P.A. Canetta, L.H. Beck Jr., R. Ayalon, J. Radhakrishnan, and G.B. Appel Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: A prospective trial Am J Nephrol 36 1 2012 58 67
39. H. Sugiura, T. Takei, and M. Itabashi et al. Effect of single-dose rituximab on primary glomerular diseases Nephron Clin Pract 117 2 2011 c98 c105
40. J.K. Deegens, and J.F. Wetzels Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial Kidney Int 80 8 2011 798 801
41. V.J. Savin, R. Sharma, and M. Sharma et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis N Engl J Med 334 14 1996 878 883
42. M. Sharma, R. Sharma, E.T. McCarthy, and V.J. Savin "The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma J Am Soc Nephrol 10 3 1999 552 561
43. E.T. McCarthy, M. Sharma, and V.J. Savin Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis Clin J Am Soc Nephrol 5 11 2010 2115 2121
44. F. Blasi, and P. Carmeliet uPAR: A versatile signalling orchestrator Nat Rev Mol Cell Biol 3 12 2002 932 943
45. H.W. Smith, and C.J. Marshall Regulation of cell signalling by uPAR Nat Rev Mol Cell Biol 11 1 2010 23 36
46. C. Wei, S. El Hindi, and J. Li et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis Nat Med 17 8 2011 952 960
47. C. Wei, H. Trachtman, and J. Li et al. Circulating suPAR in two cohorts of primary FSGS J Am Soc Nephrol 23 12 2012 2051 2059
48. J. Huang, G. Liu, and Y.M. Zhang et al. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis Kidney Int 84 2 2013 366 372
49. K. Pawlak, A. Buraczewska-Buczko, M. Mysliwiec, and D. Pawlak Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment Am J Med Sci 339 1 2010 5 9
50. A. Koch, and F. Tacke Why high suPAR is not super - diagnostic, prognostic and potential pathogenic properties of a novel biomarker in the ICU Crit Care 15 6 2011 1020
51. K. Pawlak, B. Ulazka, M. Mysliwiec, and D. Pawlak Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: A new link between angiogenesis and hyperfibrinolysis? Transl Res 160 5 2012 346 354
52. Y. Pei, D. Cattran, T. Delmore, A. Katz, A. Lang, and P. Rance Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study Am J Med 82 5 1987 938 944
53. S. Troyanov, C.A. Wall, J.A. Miller, J.W. Scholey, and D.C. Cattran Focal and segmental glomerulosclerosis: definition and relevance of a partial remission J Am Soc Nephrol 16 4 2005 1061 1068
54. D.S. Gipson, H. Trachtman, and F.J. Kaskel et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults Kidney Int 80 8 2011 868 878
55. A. Magnasco, P. Ravani, and A. Edefonti et al. Rituximab in children with resistant idiopathic nephrotic syndrome J Am Soc Nephrol 23 6 2012 1117 1124
56. Hogan J, Bomback AS, Mehta K, et al. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel [published online ahead of print September 5, 2013]. Clin J Am Soc Nephrol. http://dx.doi.org/10.2215/CJN.02840313.
57. A. Lindskog, K. Ebefors, and M.E. Johansson et al. Melanocortin 1 receptor agonists reduce proteinuria J Am Soc Nephrol 21 8 2010 1290 1298
58. V.J. Savin, E.T. McCarthy, R. Sharma, D. Charba, and M. Sharma Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity Transl Res 151 6 2008 288 292
59. E. De Smet, J.P. Rioux, H. Ammann, C. Deziel, and S. Querin FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy Nephrol Dial Transplant 24 9 2009 2938 2940
60. M. Kopac, A. Meglic, and R.R. Rus Partial remission of resistant nephrotic syndrome after oral galactose therapy Ther Apher Dial 15 3 2011 269 272
61. K.D. Jhaveri, T.H. Naber, and X. Wang et al. Treatment of recurrent focal segmental glomerular sclerosis posttransplant with a multimodal approach including high-galactose diet and oral galactose supplementation Transplantation 91 6 2011 e35 e36
62. C. Licht, and V. Fremeaux-Bacchi Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis Thromb Haemost 101 2 2009 271 278
63. F. Fakhouri, V. Fremeaux-Bacchi, L.H. Noel, H.T. Cook, and M.C. Pickering C3 glomerulopathy: A new classification Nat Rev Nephrol 6 8 2010 494 499
64. M. Levy, M.C. Gubler, M. Sich, A. Beziau, and R. Habib Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (type I MPGN) Clin Immunol Immunopathol 10 4 1978 477 492
65. R. Habib, C. Kleinknecht, M.C. Gubler, and M. Levy Idiopathic membranoproliferative glomerulonephritis in children. Report of 105 cases Clin Nephrol 1 4 1973 194 214
66. S. Sethi, C.M. Nester, and R.J. Smith Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion Kidney Int 81 5 2012 434 441
67. S.H. Nasr, A.M. Valeri, and G.B. Appel et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients Clin J Am Soc Nephrol 4 1 2009 22 32
68. S. Sethi, F.C. Fervenza, and Y. Zhang et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up Kidney Int 82 4 2012 465 473
69. M. Vivarelli, A. Pasini, and F. Emma Eculizumab for the treatment of dense-deposit disease N Engl J Med. 22 366 12 2012 1163 1165
70. S. Radhakrishnan, A. Lunn, and M. Kirschfink et al. Eculizumab and refractory membranoproliferative glomerulonephritis N Engl J Med 366 12 2012 1165 1166
71. J.A. McCaughan, D.M. O'Rourke, and A.E. Courtney Recurrent dense deposit disease after renal transplantation: An emerging role for complementary therapies Am J Transplant 12 4 2012 1046 1051
72. A.S. Bomback, R.J. Smith, and G.R. Barile et al. Eculizumab for dense deposit disease and C3 glomerulonephritis Clin J Am Soc Nephrol 7 5 2012 748 756
73. L.C. Herlitz, A.S. Bomback, and G.S. Markowitz et al. Pathology after eculizumab in dense deposit disease and C3 GN J Am Soc Nephrol 23 7 2012 1229 1237
74. S.M. Korbet, R.M. Genchi, R.Z. Borok, and M.M. Schwartz The racial prevalence of glomerular lesions in nephrotic adults Am J Kidney Dis 27 5 1996 647 651
75. J.C. Jennette, S.S. Iskandar, and F.G. Dalldorf Pathologic differentiation between lupus and nonlupus membranous glomerulopathy Kidney Int 24 3 1983 377 385
76. C. Lefaucheur, B. Stengel, and D. Nochy et al. Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association Kidney Int 70 8 2006 1510 1517
77. 2 receptor as target antigen in idiopathic membranous nephropathy N Engl J Med 361 1 2009 11 21
78. J.M. Hofstra, L.H. Beck Jr., D.M. Beck, J.F. Wetzels, and D.J. Salant Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy Clin J Am Soc Nephrol 6 6 2011 1286 1291
79. 2 receptor antibody in membranous nephropathy J Am Soc Nephrol 22 6 2011 1137 1143
80. 2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan J Biomed Sci 17 2010 81
81. H.C. Stanescu, M. Arcos-Burgos, and A. Medlar et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy N Engl J Med 364 7 2011 616 626
82. 2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy J Am Soc Nephrol 24 4 2013 677 683
83. 2R glomerular deposits in membranous nephropathy N Engl J Med 364 7 2011 689 690
84. C.D. Blosser, R. Ayalon, R. Nair, C. Thomas, and L.H. Beck Jr. Very early recurrence of anti-phospholipase A2 receptor-positive membranous nephropathy after transplantation Am J Transplant 12 6 2012 1637 1642
85. 2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy Kidney Int 82 7 2012 797 804
86. E. Hoxha, S. Harendza, and G. Zahner et al. An immunofluorescence test for phospholipase-A(2)-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis Nephrol Dial Transplant 26 8 2011 2526 2532
87. P.A. Michel, K. Dahan, and P.Y. Ancel et al. Rituximab treatment for membranous nephropathy: A French clinical and serological retrospective study of 28 patients Nephron Extra 1 1 2011 251 261
88. 2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy Kidney Int 83 5 2013 940 948
89. 2R autoantibodies and recurrent membranous nephropathy after transplantation N Engl J Med 363 5 2010 496 498
90. 2R autoantibodies predicts response in membranous nephropathy J Am Soc Nephrol 22 8 2011 1543 1550
91. C. Murtas, M. Bruschi, and G. Candiano et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy Clin J Am Soc Nephrol 7 9 2012 1394 1400
92. C. Ponticelli, P. Zucchelli, and P. Passerini et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy Kidney Int 48 5 1995 1600 1604
93. V. Jha, A. Ganguli, and T.K. Saha et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy J Am Soc Nephrol 18 6 2007 1899 1904
94. A. Howman, T.L. Chapman, and M.M. Langdon et al. Immunosuppression for progressive membranous nephropathy: A UK randomised controlled trial Lancet 381 9868 2013 744 751
95. W.A. Briggs, M.J. Choi, and P.J. Scheel Jr. Successful mycophenolate mofetil treatment of glomerular disease Am J Kidney Dis 31 2 1998 213 217
96. G. Miller, R. Zimmerman III, J. Radhakrishnan, and G. Appel Use of mycophenolate mofetil in resistant membranous nephropathy Am J Kidney Dis 36 2 2000 250 256
97. M.J. Choi, J.A. Eustace, and L.F. Gimenez et al. Mycophenolate mofetil treatment for primary glomerular diseases Kidney Int 61 3 2002 1098 1114
98. M. Polenakovic, L. Grcevska, and S. Dzikova Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy Nephrol Dial Transplant 18 6 2003 1233 1234
99. J. Ballarin, R. Poveda, and J. Ara et al. Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study Nephrol Dial Transplant 22 11 2007 3196 3201
100. T.M. Chan, A.W. Lin, and S.C. Tang et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome Nephrology (Carlton) 12 6 2007 576 581
101. L. Senthil Nayagam, A. Ganguli, and M. Rathi et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: A pilot study Nephrol Dial Transplant 23 6 2008 1926 1930
102. A.J. Branten, P.W. du Buf-Vereijken, M. Vervloet, and J.F. Wetzels Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide Am J Kidney Dis 50 2 2007 248 256
103. B. Dussol, S. Morange, and S. Burtey et al. Mycophenolate mofetil monotherapy in membranous nephropathy: A 1-year randomized controlled trial Am J Kidney Dis 52 4 2008 699 705
104. G. Xie, J. Xu, and C. Ye et al. Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: A meta-analysis based on Chinese adults PLoS One 7 9 2012 e44330
105. G. Remuzzi, C. Chiurchiu, M. Abbate, V. Brusegan, M. Bontempelli, and P. Ruggenenti Rituximab for idiopathic membranous nephropathy Lancet 360 9337 2002 923 924
106. P. Ruggenenti, C. Chiurchiu, and V. Brusegan et al. Rituximab in idiopathic membranous nephropathy: A one-year prospective study J Am Soc Nephrol 14 7 2003 1851 1857
107. F.C. Fervenza, R.S. Abraham, and S.B. Erickson et al. Rituximab therapy in idiopathic membranous nephropathy: A 2-year study Clin J Am Soc Nephrol 5 12 2010 2188 2198
108. A.S. Bomback, V.K. Derebail, J.G. McGregor, A.V. Kshirsagar, R.J. Falk, and P.H. Nachman Rituximab therapy for membranous nephropathy: A systematic review Clin J Am Soc Nephrol 4 4 2009 734 744
109. P. Ruggenenti, P. Cravedi, and A. Chianca et al. Rituximab in idiopathic membranous nephropathy J Am Soc Nephrol 23 8 2012 1416 1425
110. A. Segarra, M. Praga, and N. Ramos et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients Clin J Am Soc Nephrol 4 6 2009 1083 1088
111. B. Sprangers, G.I. Lefkowitz, and S.D. Cohen et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation Clin J Am Soc Nephrol 5 5 2010 790 797
112. P. Cravedi, P. Ruggenenti, M.C. Sghirlanzoni, and G. Remuzzi Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy Clin J Am Soc Nephrol 2 5 2007 932 937
113. J.H. Stone, P.A. Merkel, and R. Spiera et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis N Engl J Med 363 3 2010 221 232
114. R.B. Jones, J.W. Tervaert, and T. Hauser et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis N Engl J Med 363 3 2010 211 220
115. A.L. Berg, and M. Arnadottir ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses Nephrol Dial Transplant 19 5 2004 1305 1307
116. L. Picardi, G. Villa, and F. Galli et al. ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy Clin Nephrol 62 5 2004 403 404
117. T. Rauen, A. Michaelis, J. Floege, and P.R. Mertens Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24 Clin Nephrol 71 6 2009 637 642
118. C. Ponticelli, P. Passerini, and M. Salvadori et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy Am J Kidney Dis 47 2 2006 233 240
119. Berg AL, Jonsson A, Dolinina J, Bakoush O, Back S. Nephrotic patients with membranous nephropathy (MN) treated with ACTH: five year follow-up [abstract]. J Am Soc Nephrol. 2012;23:936A.
120. 2R antibody [abstract]. J Am Soc Nephrol. 2009;20:306A.